<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186186</url>
  </required_header>
  <id_info>
    <org_study_id>79130</org_study_id>
    <nct_id>NCT00186186</nct_id>
  </id_info>
  <brief_title>Depakote ER in Bipolar Depression</brief_title>
  <official_title>Depakote ER in Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar
      depression and to evaluate metabolic and GABA changes with Depakote ER administration using
      PET and MRI/MRS brain imaging techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mood disorders are important public health problems. Bipolar disorder is a major psychiatric
      disorder characterized by mood cycles alternating between mania and depression and affects
      approximately 1% of the population. Most patients are treated beginning in the early twenties
      and then embark on a course marked by multiple recurrences, hospitalizations, and encounters
      with legal authorities. These disorders inflict substantial morbidity which yields important
      deficits in occupational and interpersonal function. The risk of suicide in mood disorders
      may be as high as 10%.

      Although the outlook for recovery from acute manic or depressive episodes is generally
      excellent, the long-term prognosis of the disorder varies tremendously across the patient
      population. The introduction of lithium, anticonvulsants and atypical antipsychotics
      significantly changes the outlook for bipolar disorder, with some individuals on chronic
      treatment attaining complete remission and indefinite prophylaxis against mood episodes.
      However, such optimum outcomes may be limited to as few as one-third to one-half of all
      treated patients. The remaining experiences various combinations of breakthrough mood
      episodes, including chronic mood instability, persistent depression, and rapid cycling.

      Very little research has been conducted with bipolar disorder, and no medications have an FDA
      indication to treat bipolar depression. Previous studies suggest that Depakote is promising
      in the treatment of mixed and depressed episodes of bipolar disorder. This study utilizes the
      extended release formulation of divalproex sodium, with demonstrated increased tolerability.

      We propose investigating safety, tolerability and efficacy of Depakote ER monotherapy in
      Bipolar I, II or NOS depression, and monitoring associated changes in brain GABA levels. In
      addition, we intend to evaluate and assess the differences between brain metabolic rate and
      GABA levels in bipolar disorder patients and healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline, 7 weeks</time_frame>
    <description>The Montgomery-Ã…sberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.
Higher MADRS score indicates more severe depression the overall score ranges from 0 to 60.
Usual cutoff points are:
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to the Divalproex-ER in Acute Bipolar 2 Depression.</measure>
    <time_frame>7 weeks</time_frame>
    <description>A reduction greater than or equal to 50% in MADRS total score from baseline to the endpoint.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Depression, Bipolar</condition>
  <arm_group>
    <arm_group_label>Depakote ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depakote ER up to 1500 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote ER</intervention_name>
    <description>Depakote ER</description>
    <arm_group_label>Depakote ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bipolar I, II or NOS currently suffering from depression

          -  Both: both female and male participants are being studied

          -  Adults 18 years and older of any race

        Exclusion Criteria:

          -  Schizophrenia or schizoaffective disorder and other disorders excluded at the
             discretion of the investigator's discretion

          -  Substance dependence within the past 3 months and abuse within the past 2 weeks prior
             to study.

          -  Positive screen for psychoactive drugs, stimulants or drugs of abuse (excluding
             marijuana, as long as dependence and abuse are ruled out according to DSM-IV)

          -  Significant risk harm to self or others based on history and mental status exam

          -  Clinically significant or unstable medical condition

          -  Unstable thyroid pathology and treatment initiated or altered within the past 3 months

          -  Clinically significant abnormal laboratory test results, vital signs, as judged by the
             investigators

          -  Women pregnant or nursing, or WOCBP who do not use adequate contraception or who are
             judged to be unreliable in their use of contraception

          -  Subjects who failed (because of inefficacy or adverse effects) an adequate trial of
             Depakote; eligible patient's may not have received Depakote within 30 days of screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence A. Ketter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University, Department of Psychiatry and Behavioral Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Bipolar Disorders Clinic</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wang PW, Nowakowska C, Chandler RA, Hill SJ, Nam JY, Culver JL, Keller KL, Ketter TA. Divalproex extended-release in acute bipolar II depression. J Affect Disord. 2010 Jul;124(1-2):170-3. doi: 10.1016/j.jad.2009.10.021.</citation>
    <PMID>19923006</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>May 12, 2014</results_first_submitted>
  <results_first_submitted_qc>March 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Terrence Ketter</investigator_full_name>
    <investigator_title>Professot</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible patients were recruited from the Bipolar Disorders Clinic at the Stanford University School of Medicine in Stanford, California. Patients met DSM-IV criteria for bipolar II disorder, with a current major depressive episode, as determined by the Systematic Treatment Enhancement for Bipolar Disorder (STEP-BD)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Depakote ER</title>
          <description>Open-label. All subjects received Depakote extended release (ER) starting 250mg/daily at bedtime. Dose was increased every 4 days by 250mg/day as necessary and tolerated up to 1500 mg/day. All subjects took medication over a period of 7 weeks or terminated at the final visit (whichever came first).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported as to reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Depakote ER</title>
          <description>Depakote ER up to 1500 mg/day
Depakote ER: Depakote ER</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The Montgomeryâ€“Ã…sberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.
Higher MADRS score indicates more severe depression the overall score ranges from 0 to 60.
Usual cutoff points are:
0 to 6 â€“ normal/symptom absent 7 to 19 â€“ mild depression 20 to 34 â€“ moderate depression &gt;34 â€“ severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
        <description>The Montgomeryâ€“Ã…sberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.
Higher MADRS score indicates more severe depression the overall score ranges from 0 to 60.
Usual cutoff points are:
0 to 6 â€“ normal/symptom absent 7 to 19 â€“ mild depression 20 to 34 â€“ moderate depression &gt;34 â€“ severe depression.</description>
        <time_frame>Baseline, 7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Depakote ER</title>
            <description>Depakote ER up to 1500 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>The Montgomeryâ€“Ã…sberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.
Higher MADRS score indicates more severe depression the overall score ranges from 0 to 60.
Usual cutoff points are:
0 to 6 â€“ normal/symptom absent 7 to 19 â€“ mild depression 20 to 34 â€“ moderate depression &gt;34 â€“ severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to the Divalproex-ER in Acute Bipolar 2 Depression.</title>
        <description>A reduction greater than or equal to 50% in MADRS total score from baseline to the endpoint.</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Depakote ER</title>
            <description>Open-label. All subjects received Depakote extended release (ER) starting 250mg/daily at bedtime. Dose was increased every 4 days by 250mg/day as necessary and tolerated up to 1500 mg/day. All subjects took medication over a period of 7 weeks or terminated at the final visit (whichever came first).</description>
          </group>
        </group_list>
        <measure>
          <title>Response to the Divalproex-ER in Acute Bipolar 2 Depression.</title>
          <description>A reduction greater than or equal to 50% in MADRS total score from baseline to the endpoint.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>54</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Depakote ER</title>
          <description>Depakote ER up to 1500 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Weight gain</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>â‰¥ 7% Weight gain</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial is limited by small sample size, as well as an open-label study design with no placebo control.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Terence Ketter, Chief Bipolar Disorder Clinic</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-2515</phone>
      <email>tketter@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

